News >

Navigating Frontline Treatment With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Jessica Hergert
Published: Tuesday, Jan 14, 2020

Denise Yardley, MD

Denise Yardley, MD

With the approval of 3 CDK4/6 inhibitors, the frontline landscape of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer has evolved with chemotherapy no longer being the go-to approach, said Denise Yardley, MD. 

In March 2017, the FDA granted a full approval to palbociclib (Ibrance) in combination with letrozole as a frontline treatment for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, based on data from the confirmatory phase III PALOMA-2 trial. Palbociclib is also indicated for use in combination with other aromatase inhibitors (AIs) in this setting.

In April 2019, the indication for palbociclib plus an AI was expanded to include men with HR-positive, HER2-negative advanced or metastatic breast cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication